Physician profile
David Patrick Hurd
NPI 1851858252
$2,413.72
in general payments reported to CMS, 2019-2025
20 companies · $571 in 2025
The $571 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $192 · 2021: $444 · 2022: $352 · 2023: $463 · 2024: $115 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $313.40 | 2019-2021 | |
| Alcon Vision LLC | $309.26 | 2021-2025 | Hydrus Microstent, Total30, Precision7 |
| Abbvie INC. | $269.21 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $227.34 | 2022-2025 | Infuse |
| Tarsus Pharmaceuticals, INC. | $220.37 | 2024-2025 | Xdemvy |
| Allergan, INC. | $126.64 | 2020-2022 | |
| Dompe US, INC. | $125.37 | 2020-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $122.43 | 2019-2020 | |
| Oyster Point Pharma, INC. | $122.12 | 2022 | |
| Maculogix, INC. | $102.44 | 2021 | |
| Coopervision INC. | $98.80 | 2021-2023 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $74.46 | 2019-2020 | |
| Optos, INC. | $63.12 | 2021 | |
| Topcon Healthcare, INC. | $61.72 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $46.73 | 2023 | Acuvue |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $41.73 | 2025 | |
| Carl Zeiss Meditec, INC. | $24.83 | 2020 | |
| Amgen INC. | $24.00 | 2025 | Tepezza |
| Lumibird Medical INC. | $23.07 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hurd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.